SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
FDA: Toxicity Seen In Fatal French Study Does Not Extend To Other FAAH Inhibitors
August 15, 2016
 · 
1 min read
Boston Scientific Commits to 10 More Years in SoCal Space, Plans to Hire
Drug Development
Vaxart Challenges Takeda with Oral Norovirus Vaccine
August 8, 2016
 · 
3 min read
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
Drug Development
AstraZeneca PLC Kills Six Pipeline Programs
July 28, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths
July 15, 2016
 · 
3 min read
How Biogen Makes Most of Its Cash
Drug Development
With Little Fanfare, Biogen Sneaks Lupus Drug Into a Phase I Trial
July 14, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
3 Nauseating Clinical Trial Flops of 2016 So Far
July 11, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Scancell Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine
July 7, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
This Year’s Top 10 Disappointing Clinical Trials—So Far!
July 5, 2016
 · 
3 min read
First-Ever CRISPR Trials Points To Looming Problems
Biotech Bay
First-Ever CRISPR Trial Points to Looming Problems
June 27, 2016
 · 
5 min read
Biotech Startups Flock to the Suburbs Over Rising Rent Prices
Drug Development
Kite Pharma and Juno’s R&D Strategy to Reshape Cancer Treatment
June 21, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026
 · 
4 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease
January 15, 2026
 · 
2 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
January 13, 2026
 · 
6 min read
Press Releases
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
January 13, 2026
 · 
4 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
 · 
9 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
 · 
9 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
January 12, 2026
 · 
3 min read
Press Releases
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
January 12, 2026
 · 
1 min read
Press Releases
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
 · 
5 min read
Press Releases
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
January 12, 2026
 · 
5 min read
Press Releases
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
January 12, 2026
 · 
4 min read
Press Releases
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
January 12, 2026
 · 
7 min read
Press Releases
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
January 12, 2026
 · 
3 min read
Load More